Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of ...
Merck , known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SCtm (pembrolizumab injection), a new subcutaneous formulation of pembrolizumab, ...
The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing ...
Gilead Sciences, Inc. today announced details of new clinical and real-world data from its innovative HIV treatment and ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...
The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.
Dr. Ashkan Emadi, principal investigator of a first-in-world phase 2 clinical trial evaluating subcutaneous Blincyto ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results